Key Takeaways
- Tempsens Instruments is launching a book-built IPO of 2,16,66,666 shares at a price band of ₹285–₹300, raising up to ₹650 crore.
- The single biggest signal: the issue is dominated by an OFS of 1,85,00,000 shares (up to ₹555 crore), so the float is seller-heavy.
- Key risk: listing pressure from the large OFS and a reported market cap of ₹2,514.98 crore versus FY26 PAT of ₹71.07 crore implies a high implied multiple (~35x).
- Watchlist – wait for GMP, subscription numbers and the announced quota splits (QIB/NII/Retail) before applying.
What Is Tempsens Instruments' Business And Corporate Background?
this is a main-board IPO of 2,16,66,666 equity shares of face value ₹4 aggregating up to ₹650 crore, proposed to list on BSE and NSE; The company’s red herring prospectus (RHP) presents the offering as a mix of fresh capital and an offer-for-sale and sets out the statutory and market-facing particulars required for a public listing. The RHP is the primary public document for the detailed corporate narrative, and this section confines itself to facts disclosed there.
The RHP lists a reported market capitalisation of ₹2,514.98 crore. It also names the transaction advisers and administrative agents that will manage the public offering: Lead Managers are ICICI Securities Ltd. and JM Financial Ltd., and the Registrar to the issue is Kfin Technologies Ltd. The filing classifies the issue as a book-built IPO and sets the framework for allocation across investor categories and the timetable for subscription, allotment and listing.
Because the source material limits descriptive detail, this background focuses on the filing-level facts investors need at a glance: the RHP status, the offer size and share count, the proposed exchanges for listing, the declared market cap and the adviser names. For readers who want to move from these headline facts to application steps or a side-by-side comparison with other upcoming issues, consider using Swastika's Sarthi AI stock assistant to drill into the RHP and related documents.
How Is The IPO Sized And Split Between Fresh Issue And Offer-For-Sale?
Tempsens' public offer is divided into two clear tranches: a fresh issue of 31,66,666 equity shares (aggregating up to ₹95 crore) and an offer-for-sale of 1,85,00,000 shares (aggregating up to ₹555 crore). Together they total 2,16,66,666 shares (up to ₹650 crore). Because a substantial majority of the volume is secondary stock, the cash from most shares will flow to selling shareholders rather than into the company's balance sheet.
Why a large OFS matters to listing dynamics
- Supply pressure on listing day: A dominant OFS increases the quantum of stock entering the market immediately; if demand–especially from institutional buyers–fails to match that supply, the listing-day upside can be constrained.
- Proceeds and company objectives: Only the fresh portion augments corporate resources (the stated use of proceeds will be in the RHP); the larger OFS tranche redirects most cash to sellers, which alters the capital-raising narrative.
- Signalling effect: Who is selling matters. Large secondary sales by early investors or promoters can be read as liquidity-taking and influence investor sentiment; check seller identities and any lock-in exemptions disclosed in the offer documents.
- Liquidity versus price impact: While OFS can improve free float and post-listing liquidity, it can also create immediate selling pressure. The balance between these outcomes will depend on demand across QIB, NII and retail segments on subscription and on allocation patterns.
Before applying, investors should review the RHP for the detailed OFS seller list, lock-in terms and the company's stated use for the fresh proceeds–those specifics will be decisive in assessing listing risk and reward.
What Are The Key Dates – When Does The Issue Open, Allot And List?
IPO open 20 Aug 2026, close 24 Aug 2026, allotment date Tue, Aug 25, 2026, refund date Thu, Aug 27, 2026 and listing date Fri, Aug 28, 2026; note exchanges BSE and NSE.
These are the working dates investors should pencil into their calendars. The schedule sets a short, visible sequence from subscription through allotment, refund activity and public listing; treat each date as a trigger for a specific check: confirmation of application acceptance during the window, watching the allotment announcement, verifying refund credit if allocation is not received, and monitoring the market debut for execution decisions. Given the compact timeline, operational readiness–correct demat details, valid payment mandate and timely broker instructions–matters as much as the investment decision itself.
- Confirm demat account name and number match your broker records and that your payment route (ASBA or UPI) is active.
- Keep application confirmations and reference numbers handy for follow-up with the registrar if needed.
- On allotment date, consult the registrar's announcement and your broker's portal to check allocation status; use the refund date to verify any returned funds.
- Decide in advance whether to hold or place sell orders when the stock begins trading on BSE and NSE on the listing date.
Use these dates as operational mileposts: they won't change without formal disclosure, so incorporate them into your execution plan ahead of the opening date.
How Much Will It Cost Me To Apply – What's The Price Band, Lot Size And Minimum Ticket?
The IPO is being offered in a price band of ₹285 to ₹300 per share and applications must be placed in a minimum lot of 50 shares. Retail bidders are required to apply only in lots of 50 – that is the smallest permitted allocation unit and any application that does not conform to the 50-share multiple will be rejected by the registrar or broker.
Minimum-ticket calculation
Using the upper end of the band to show the out of pocket requirement, one retail lot at ₹300 per share equals ₹15,000 (50 ₹300 = ₹15,000) – this is the minimum cash value that must be available/blocked for a retail application at the cut off price. If you bid for more than one lot, multiply ₹15,000 by the number of lots you intend to apply for; the total amount will be blocked in ASBA or held as a UPI mandate until allotment or refund.
For reference, the shares have a face value of ₹4 each – a bookkeeping denomination separate from the issue price. When planning an application, ensure your bank/UPI limits cover the blocked amount for your chosen number of lots and double check demat details so allotment credits can be received smoothly.
Because the minimum ticket at the top band is ₹15,000, investors who normally aim for smaller IPO exposures should note this as the starting commitment. If you prefer a lower-entry route, consider waiting for the secondary market after listing or participating via pooled vehicles that access IPO allocations.
Who Are The Lead Managers, Registrar And What Type Of Offer Is This?
ICICI Securities Ltd., JM Financial Ltd. have been engaged as the lead managers for the transaction; Kfin Technologies Ltd. is appointed as the registrar. The company has filed a Bookbuilding IPO and is offering shares through a Fresh capital cum OFS structure.
While those names and the issue format are a basic fact on the face of the RHP, their practical importance lies in execution. In a book-built deal the lead managers judge oversubscription, collate bids across institutional and retail channels and steer the final pricing decision; their distribution networks and institutional relationships therefore shape demand during the subscription window. As registrar, Kfin Technologies Ltd. will be the operational interface for allotment processing, refund management and post-issue investor communications – including the allotment status and crediting of shares to demat accounts.
For an offer combining fresh issue and OFS, watch how the lead managers allocate across investor categories and how they handle potential secondary selling pressure on listing. The RHP will hold the concrete disclosures: the list of selling shareholders, any underwriting commitments, lock in provisions and the registrar’s contact points for investor queries. Investors who track execution quality (timely allotment announcements, accurate refunds and transparent communications) often use these operational signals as a complement to the financial analysis when deciding whether to participate.
Prior to subscribing, investors comfortable with monitoring bookrunning developments and registrar communications may find participation more manageable; those who prefer minimal operational involvement should weigh waiting for the secondary market or seeking allocations through managed portfolios.
What Do The Company's Financials Show (Revenue, PAT, Net Worth, Borrowings)?
The RHP discloses financial results for the periods ended 31 Mar 2026 and 31 Mar 2025; the table below reproduces those headline figures. Over that span the company expanded revenue and reported profit while also strengthening its equity base. Reported revenue moved to ₹455.86 Cr from ₹382.47 Cr and PAT rose to ₹71.07 Cr from ₹62.56 Cr. Net worth increased to ₹496.89 Cr from ₹430.63 Cr, and borrowings were marginally higher at ₹77.95 Cr versus ₹71.83 Cr. These raw figures are the starting point for assessing operational performance and balance sheet resilience.
Two growth observations stand out and should guide further reading of the prospectus. First, headline revenue growth exceeded PAT growth, indicating that incremental top line gains translated into smaller proportional profit increases; investors should consult the RHP’s cost and margin disclosures to determine whether this reflects higher input costs, elevated operating expenses tied to expansion, tax impacts or one off items. Second, net worth has expanded alongside a modest rise in borrowings, a combination that can support organic investment without immediate heavy reliance on external debt – nevertheless, examine working capital trends, contingent liabilities and planned capital expenditure in the filing to judge sustainability. Use the table below as a factual base for those follow ups.
| Period | Revenue (₹ Crore) | PAT (₹ Crore) | Net Worth (₹ Crore) | Borrowings (₹ Crore) |
|---|---|---|---|---|
| 31 Mar 2026 | ₹455.86 Cr | ₹71.07 Cr | ₹496.89 Cr | ₹77.95 Cr |
| 31 Mar 2025 | ₹382.47 Cr | ₹62.56 Cr | ₹430.63 Cr | ₹71.83 Cr |
Revenue YoY growth: +19.2%
PAT YoY growth: +13.6%
Is Tempsens Instruments Growing – How Strong Are Revenue And Profit Trends?
The RHP numbers supply the raw increases; here we focus on what those moves mean for profitability and balance sheet strength. Looking beyond totals helps judge whether growth is translating into durable shareholder value or simply higher turnover.
Margins, conversion and leverage
Margin analysis shows a small but noticeable shift: the company’s PAT margin narrowed by roughly 0.8 percentage point year on year, to about 15.6% in the latest reported year. That decline suggests that the incremental sales were earned at slightly lower net profitability than the prior period. Quantifying conversion, only about 11.6% of the additional sales in the most recent year flowed through as extra PAT – a useful metric for gauging operating leverage and cost absorption on newer revenue.
On the financing side, the equity cushion expanded faster than borrowings, so leverage eased modestly: borrowings as a share of net worth fell by roughly one percentage point to about 15.7%. In plain terms, nominal debt inched up but the company strengthened its equity base more, lowering financial risk on a relative basis.
Bottom line: the firm is growing, and its balance sheet exhibited a marginal improvement in leverage, but profitability per rupee of sales showed a slight softening. Investors should check the RHP’s cost breakdown, segmental margins and one off items to determine whether margin pressure is temporary or structural before drawing conclusions about earnings quality.
How Expensive Does The IPO Look Using The RHP Market Cap And FY26 Profit?
A simple market-cap-to-trailing-profit check using the figures named in the RHP produces a quick valuation cue. Dividing the stated market capitalisation (₹2,514.98 Crore) by the company’s reported FY26 PAT (₹71.07 Crore) yields an implied price to earnings multiple of roughly 35x. Treat this as a blunt, back of the envelope screen rather than a definitive price signal.
Why the number is only a starting point: it is a trailing, equity value multiple that ignores balance sheet nuances, expected future earnings, and the capital structure effects that an IPO can create. A like for like judgment requires comparing this trailing P/E with peers on the same basis (trailing versus forward) and, where appropriate, switching to enterprise value metrics that fold in debt and cash. Small accounting items or one time gains in the reported PAT can also move a multiple materially when the denominator is comparatively small.
Use the implied mid 30s multiple as an initial filter: it signals the valuation band to explore, not the final verdict. The sensible next steps for investors are to benchmark this multiple against listed peers in instrumentation and industrial controls, check forward earnings assumptions and management guidance in the RHP, and revisit the calculation after adjusting for any post issue share count or balance sheet changes disclosed before listing. Only then can you judge whether the IPO’s headline multiple represents a premium that growth justifies or a level that warrants caution.
Why Does The Large OFS Matter For Retail Investors And Listing Outcomes?
Tempsens is offering a substantially larger secondary component than primary: 1,85,00,000 shares are being sold via OFS (up to ₹555Cr) versus only 31,66,666 fresh shares (up to ₹95Cr). For retail buyers this ratio reshapes how the market determines the opening price: with a preponderance of tradable stock originating from existing holders, early trading dynamics will depend heavily on whether those allocations are held, rotated among intermediaries or converted into immediate sell orders.
Bookrunners and institutional bidders often absorb large secondary lots, which can mean that the retail portion is relatively thin and that individual allotments are modest. When the immediate holders of large blocks prefer short term exits, the early order book can skew to selling interest, producing wider intraday swings and reducing the probability of a sharp first day gain even if the company’s fundamentals are sound.
That makes investor intent pivotal: if you’re targeting a quick listing profit, be conservative with bid size and expectations; if you’re a longer term buyer, focus on valuation and management strategy rather than anticipated shallow aftermarket pops. Pay close attention to who takes the allocations and any post offer holding commitments disclosed in the prospectus – those are practical signals about whether the initial market will find steady buyers or be dominated by short duration sellers.
Finally, watch the bookbuilding and grey market cues as the issue closes and monitor allotment outcomes: they will reveal whether demand is anchored in holders likely to provide support or concentrated in counterparties that may monetise positions swiftly after listing.
What Are The Specific Risks Investors Should Weigh Before Applying?
Before placing an application, consider four concrete, document supported risks that can materially affect listing outcomes and medium term returns.
- High proportion of secondary supply: A large slice of the offered shares are being sold by existing holders, which meaningfully increases the immediately tradable float. That concentration can amplify directional flows if sizeable blocks move into the market soon after listing or if allocations are clustered with a few large counterparties; both scenarios can prolong weak price momentum. Review the RHP for seller identities and any lock in arrangements.
- Valuation sensitivity: The stated equity valuation versus reported profit implies elevated market expectations. In such settings, modest shortfalls in growth or margin recovery are likely to trigger outsized re-rating, making the issue less forgiving for investors targeting a quick uplift rather than sustained earnings delivery.
- Opaque demand signals: Key market cues – grey market premium, formal subscription tallies and the final quota distribution – are not available at present. Those data points are essential to judge allotment probability and the likely balance of buy/sell interest on listing day; their absence increases uncertainty around allocation and early aftermarket behaviour.
- Leverage and financial flexibility: Borrowings are reported at ₹77.95 Crore as of 31 Mar 2026. While this does not suggest high indebtedness, debt service needs reduce operational flexibility if cash generation softens. Check the RHP for any explicit plans to use proceeds for de leveraging or for working capital support, since limited corrective options would be a downside risk.
What Is The Grey Market Premium (GMP) Now And What Would It Tell Me?
Per the source, the grey market premium is 'Not available yet'. The GMP is an informal, over the counter quote produced by dealers and brokers before formal trading begins; it is not an exchange disclosure but a shorthand for immediate aftermarket sentiment. When a GMP appears it provides a near term gauge of whether buyers or sellers are likely to dominate the stock’s public debut, making it useful as a short term sentiment overlay rather than a regulatory metric.
When to monitor
Follow GMP readings in the sessions immediately before the market debut and after the subscription window closes. Look at the sequence of quotes rather than a single print: a steady rise across readings points to strengthening appetite, while a falling GMP signals cooling interest. Always cross reference grey market signals with formal subscription and allotment details once they are released to get a fuller picture.
How to interpret GMP given a large OFS
When a large portion of the offer is secondary, interpret GMP with extra care. A clear positive GMP in that environment suggests demand sufficient to absorb selling by existing holders and improves the odds of a stable or firm open. A muted or negative GMP, by contrast, indicates selling pressure may overwhelm early bids and that the listing could be weak. Remember that GMP can be thin, anecdotal and occasionally distorted; use it as one directional input alongside subscription data and the company’s fundamentals rather than as the sole basis for your decision.
What Are My Allotment Odds As A Retail Investor And When Will Quota Splits Be Announced?
At this stage the precise quota splits for retail, NII and QIB categories remain to be announced, so calculating firm allotment odds is not possible. The core operational reality retail investors should focus on is application granularity: bids must be placed in lots of 50 shares. Because allotment is delivered in whole lot units, the lot size creates a step function effect – a single lot applicant may either receive one entire lot or none, depending on how the final retail demand divides against the retail tranche.
What will unlock the odds
Once the issue closes, the registrar and the bookrunners will publish subscription tallies and the final quota breakdown; those published numbers are the only inputs that let you convert demand data into a probability of receiving one or more lots. In practical terms, investors can estimate their likely allocation by dividing the retail tranche (in shares) by total retail demand (in shares) to obtain a scaling factor, then applying that factor to the shares they requested – remembering that the result is adjusted to whole lots and subject to tie breaking rules. Until those tallies are released, any attempt to state odds is speculative.
How to prepare
Keep your application reference and demat details ready for the allotment announcement, and be mentally prepared for scaled allocations if you applied for only a few lots. Monitor the post issue subscription report as soon as it is released to convert the disclosed tallies into a clear allotment expectation.
Before you begin
Complete basic housekeeping: ensure your PAN and KYC are active in your depository account, that your demat is enabled to receive IPO credits, and that the bank account or UPI ID you intend to use is functional. Confirm with your bank or broker that ASBA and UPI mandates are activated in their IPO facility. Submit well before 24 Aug 2026 to avoid last minute rejections.
Applying via ASBA (bank or broker portal)
- Log in to your bank’s netbanking ASBA section or to your broker’s ASBA interface and locate the Tempsens Instruments IPO tile.
- Choose the retail category, enter the number of lots (multiples of 50 shares) and select your price preference within the band as allowed by the platform.
- Select the savings/current account to be blocked under ASBA and authorise the mandate; note the application reference number returned by the system and retain a screenshot.
Applying via UPI (broker mobile app)
- Open your broker app, pick the IPO, specify lots in 50 share multiples and confirm the price instruction.
- Select UPI as payment method and enter your UPI ID. On submission you will receive a UPI mandate request in your UPI app–approve it promptly; unapproved mandates can lead to application rejection.
- Save the UPI mandate ID or transaction reference shown after approval; this is useful for follow up if a debit appears unexpectedly.
After submission, track allotment and refunds via the registrar, Kfin Technologies Ltd–allotment will be processed on 25 Aug 2026 and refunds (or release of ASBA blocks) on 27 Aug 2026. If allotment is received, verify demat credit; if not, contact your broker and Kfin with your application reference.
Pros
The filing points to a company that has built operational momentum and a stronger capital base, creating optionality for reinvestment and strategic moves without immediate recourse to heavy external finance. Lower relative leverage enhances flexibility: management can prioritise product development, working capital and selective capacity additions while keeping interest exposure manageable. Solid, repeatable earnings performance also improves the credibility of the story for long term institutional holders, which can help smooth price discovery beyond the listing day.
Cons
The transaction structure elevates supply side uncertainty because a large portion of the offer is secondary stock; who takes and how quickly those shares are monetised will materially affect early liquidity and price trajectory. Valuation is demanding by headline checks, so execution risk and margin pressures would have an outsized effect on returns if growth slows. Critically, two market signals that determine allotment odds and short term direction–the grey market premium and the post issue subscription splits–are not yet available and will be published in the run up to allotment; their absence leaves initial outcomes hard to model.
Final call
If you are targeting a quick listing gain, stand aside until grey market readings and subscription tallies show a clear, positive bias. Long term investors who have done detailed RHP due diligence and accept early volatility can consider participation, but only after confirming subscription strength and any seller lock in terms. In short: monitor grey market and subscription data closely – use those signals as the decisive trigger before committing capital.
Frequently Asked Questions
When does the Tempsens Instruments IPO open and when will shares list?
The IPO opens on 20 Aug 2026 and closes on 24 Aug 2026; allotment is scheduled for 25 Aug 2026, refunds on 27 Aug 2026 and listing on 28 Aug 2026 on BSE and NSE.
What is the price band, lot size and minimum investment for the IPO?
The price band is ₹285 to ₹300 per share, the minimum order quantity (lot size) is 50 shares and the minimum retail ticket is ₹15,000 (at the upper band); face value is ₹4 per share.
Is there a grey market premium (GMP) and should I expect listing gains?
GMP is reported as 'Not available yet' in the source; without a GMP and subscription numbers you cannot reasonably forecast listing gains—listing outcome will depend on demand, the large OFS and QIB/retail appetite.
What is the biggest risk in this IPO?
The largest risk is the seller‑dominated structure: 1,85,00,000 shares via OFS (up to ₹555Cr) versus only 31,66,666 fresh shares (up to ₹95Cr), which can create listing pressure; additionally the RHP shows a market cap of ₹2,514.98 Cr against FY26 PAT of ₹71.07 Cr implying an elevated valuation (~35x).
How will allotment be determined and what are my chances as a retail investor?
Allotment will follow the announced quota splits and subscription levels; quota details (QIB/NII/Retail) are to be announced and subscription numbers are not yet available, so retail allotment odds cannot be calculated until after the issue closes.
How do I apply via ASBA or UPI?
Apply through your broker or bank ASBA or via UPI mandate by selecting lots of 50 shares within the ₹285–₹300 band, block funds through ASBA or approve the UPI mandate before the close date (24 Aug 2026); retain application acknowledgements and watch allotment on 25 Aug 2026.
Conclusion
Tempsens Instruments' IPO offers a company with steady revenue and profit growth (Revenue ₹455.86 Cr and PAT ₹71.07 Cr in FY26) and a solid net worth, but the supply/demand picture is distorted by a large OFS that dominates the offer. Important details that will decide the short term outcome–GMP, subscription numbers and the final quota splits–are not available yet, and the RHP shows an implied valuation that demands close scrutiny.
Watchlist – wait for GMP, subscription and quota details while the large OFS raises listing uncertainty.
